Edwards Lifesciences Reports Strong Q4 and Full-Year 2025 Results

Details

The company saw strong growth in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments, contributing to an adjusted EPS of $0.58 for Q4 and $2.56 for the full year. Edwards also provided an optimistic outlook for 2026, projecting sales growth of 8-10% and adjusted EPS between $2.90 and $3.05.

Items reported

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a leading healthcare company primarily known for its innovative medical devices focused on cardiovascular conditions. The firm's primary function revolves around the development and commercialization of heart valve products and hemodynamic monitoring systems, aimed at enhancing the life quality of patients suffering from cardiovascular diseases. Edwards Lifesciences plays a crucial role in the healthcare sector, particularly impacting the cardiology and surgical fields. Notable for its pioneering work in heart valve therapies, the corporation is at the forefront of transcatheter aortic valve replacement (TAVR) technology, a minimally invasive procedure that offers a significant alternative to traditional open-heart surgeries. Edwards Lifesciences collaborates closely with healthcare professionals to ensure its products address critical medical needs globally. Headquartered in Irvine, California, Edwards Lifesciences operates in a highly competitive and rapidly advancing market, where technological innovation and patient outcomes are pivotal. Its contributions continue to set standards within the medical device industry, reinforcing its market significance by addressing demands for effective cardiovascular care solutions worldwide.